- AQB recently closed a public offering for financing its expansion of a new farm with a 10,000 metric ton production capacity.
- Comparable analysis of U.S. competitor Atlantic Sapphire would increase the value of AQB by 2x when the new farm reaches full capacity.
- Institutional ownership is high, suggesting future belief in the company.
- Particularly interest-rate sensitive as it is a part of the biotech sector and intermediate downside volatility should be viewed as a potential entry point.
- Risk of consumers choosing conventionally farmed salmon opposed to GMO-farmed AquAdvantage salmon could diminish revenue streams.
For further details see:
AquaBounty Technologies: Faster Growing Salmon, Faster Profits